Given the extensive neovascularization observed in more advanced stages of ccRCC, the therapeutic approach has predominantly revolved around targeting the VEGF signaling pathway using TKIs or monoclonal antibodies that specifically inhibit VEGF [13, 14]. Here, VEGFA is linked to nonpapillary renal cell carcinoma.